· Журналы · Книги · О проекте ·Электронные версии книг издательства “Атмосфера” поступили в продажу Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru ИНТЕРНЕТ-МАГАЗИН    Лечебное дело 2013 / N 3 Комбинация лозартана и гидрохлоротиазида: несомненный плюс (список литературы) А.В. Мелехов, Ю.И. Островская Список литературы: 1. Российское медицинское общество по артериальной гипертонии (РМОАГ), Всероссийское научное общество кардиологов (ВНОК). Диагностика и лечение артериальной гипертензии. Российские рекомендации (4-й пересмотр). Системные гипертензии. 2010; 3: 3–25 2. 2013 ESH/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Journal of Hypertension 2013, 31:1281–1357. 3. Guidelines for the management of spontaneous intracerebral hemorrhage in adults. 2007 update: a guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group 4. Swedberg K., Kjekshus J., Snapinn S. Long-term survival in severe heart failure in patients treated with enalapril. Ten year follow-up of CONSENSUS I. Eur Heart J 1999;20:136–139. 5. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685–691. 6. Jong P., Yusuf S., Rousseau M.F., et al. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet 2003;361(9372):1843–1848. 7. Sun JY, Zhai L, Li QL, Ye JX, Kang LN, Xie J, Xu B. Effects of ACE inhibition on endothelial progenitor cell mobilization and prognosis after acute myocardial infarction in type 2 diabetic patients. Clinics (Sao Paulo). 2013 May;68(5) 8. Peters R, Beckett N, Poulter R, Burch L, Narkiewicz K, Fagard R, Nitsch D, Wang N, Li M, Fletcher A, Bulpitt C. Kidney function in the very elderly with hypertension: data from the hypertension in the very elderly (HYVET) trial. Age Ageing. 2013 Mar;42(2):253-8 9. Cleland JG, Taylor J, Freemantle N, Goode KM, Rigby AS, Tendera M. Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-CHF study. Eur J Heart Fail. 2012 May;14(5):487-94 10. Tu K., Mamdani M., Kopp A., Lee D. Comparison of angiotensin-converting enzyme inhibitors in the treatment of congestive heart failure. Am J Cardiol 2005;95(2):283–286 11. Savarese G, Costanzo P, Cleland JG et al. A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with outheart failure. J Am Coll Cardiol 2013; 61: 131–42. 12. Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Prefer redreporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009; 62: 1006–12. 13. Van Vark LC, Bertrand M, Akkerhuis KM et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors in volving 158,998 patients. Eur Heart J 2012; 33: 2088–97 14. Pickering TG, Miller NH, Ogedegbe G, et al: American Heart Association; American Society of Hypertension; Preventive Cardiovascular Nurses Association: Call to action on use and reimbursement for home blood pressure monitoring: A joint scientific statement from the American Heart Association, American Society Of Hypertension, and Preventive Cardiovascular Nurses Association. Hypertension. 2008, 52: (1): 10-29 15. Lindholm LH, Ibsen H, Dahlot B et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004–10 16. Liao Y, Cooper R, Mensah G et al. The relative effects of left ventricular hypertrophy, coronary artery disease, and ventricular dysfunction on survival among black adults. JAMA 1995; 273: 1592–7 17. Burns J, Ball SG, Worthy G, Struthers AD, Mary DA, Greenwood JP. Hypertensive left ventricular hypertrophy: a mechanistic approach to optimizing regression assessed by cardiovascular magnetic resonance. J Hypertens. 2012 Oct;30(10):2039-46. 18. Nakamura T, Fujii S, Hoshino J et al. Selective angiotensin receptor antagonism with valsartan decreases arterial stiffness independently of blood pressure lowering in hypertensive patients. Hypertens Res 2005; 28 (12): 937–43 19. Lewington S, Clarke R, Qizilbash N et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Prospective Studies Collaboration. Lancet 2002; 360: 1903–13 20. Blood Pressure Lowering Treatment Trialists Collaboration. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 2007; 25: 951–8. 21. Dahlof B, Devereux RB, Kristiansson K et al. LIFE study group. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study: a randomized trial against atenolol. Lancet 2002; 359: 995–1003 22. Mennuni S, Rubattu S, Pierelli G, Tocci G, Fofi C, Volpe M. Hypertension and kidneys: unraveling complex molecular mechanisms underlying hypertensive renal damage. J Hum Hypertens. 2013 Jun 27. doi: 10.1038 23. Halimi JM, Asmar R, Ribstein J. Optimal nephroprotection: use, misuse and misconceptions about blockade of the renin-angiotensin system. Lessons from the ONTARGET and other recent trials. Diabetes Metab. 2009 Dec;35(6):425-30. 24. Lindholm LH, Ibsen H, Danlof B, et al, for the LIFE study group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:1004-10 25. Национальные Рекомендации ВНОК И ОССН по диагностике и лечению ХСН (второй пересмотр) // Журнал сердечная недостаточность. 2007; 8: 2 26. Pitt B., Segal R., Martinez F.A. et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) // Lancet. 1997; Mar; 15: 349: 9054: 747–752. 27. Shahinfar S., Lyle P.A., Zhang Z. et al. Losartan: lessons learned from the RENAAL study // Expert Opin Pharmacother. 2006; Apr; 7: 5: 623–630 28. Mychka V., Gornostaev V., Dmitriev V. et al. Effect of perindopril on 24-hours ambulatory blood pressure monitoring, carbohydrates and lipids metabolism in patients with mild and moderate arterial hypertension and metabolic syndrome // J. Hypertens. — 2001. — 19 (suppl 2). — S283 29. Jennings A.M., Wilson R.M., Ward J.D. Symptomatic hypoglycemic agents // Diabetes Care. — 1989. — 12. — 201-208 30. Chobanian A.V., Bakris G.L., Black H.R. et al. Seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. Hypertension. 2003;42:1206–1252. 31. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003;21:1983–1992 32. Chobanian A.V., Bakris G.L., Black H.R. et al. Seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. Hypertension. 2003;42:1206–1252. 33. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in elder persons with isolated systolic hypertension. Final results of the systolic hypertension in the elderly. Programm (SHEP). JAMA, 1991; 296: 887-9. 34. Mattila K., et al. Blood pressure and five year survival in the very old. BMJ. 1989; 298:1356-8. 35. Dahlot B., et al. Morbility and mortality in the Swedish Trial in old patients with hypertension (STOP-Hypertention). Lancet, 1991; 338: 1181-5 36. Reid IR, Ames RW, Orr-Walker BJ, Clearwater JM, Horne AM, Evans MC, Murray MA, McNeil AR, Gamble GD. Hydrochlorothiazide reduces loss of cortical bone in normal postmenopausal women: a randomized controlled trial. Am J Med. 2000 Oct 1;109(5):362-70. 37. Hosoya T, Kuriyama S, Yoshizawa T, Kobayashi A, Otsuka Y, Ohno I. Effects of combined antihypertensive therapy with losartan/hydrochlorothiazide on uric acid metabolism. Intern Med. 2012;51(18):2509-14. 38. Fujimori S, Oka Y, Ogata N, Eto K. Effects of losartan/hydrochlorothiazide on serum uric acid levels and blood pressure in hypertensive patients. Nucleosides Nucleotides Nucleic Acids. 2011 Dec;30(12):1030-4. 39. Ohshiro K, Sakima A, Nakada S, Kohagura K, Yamazato M, Tana T, Ohya Y. Beneficial effect of switching from a combination of angiotensin II receptor blockers other than losartan and thiazides to a fixed dose of losartan/hydrochlorothiazide on uric acid metabolism in hypertensive patients. Clin Exp Hypertens. 2011;33(8):565-70. 40. Salerno C.M., Demopoulos L.,Mukherjee R., et al. Combination angiotensin receptor blocker/hydrochlorothiazide as initial therapy in the treatment of patients with severe hypertension. J Clin Hypertens (Greenwich) 2004 Nov; 6 (11): 614-20 41. Sato N, Saijo Y, Sasagawa Y, Morimoto H, Takeuchi T, Sano H, Koyama S, Takehara N, Morita K, Sumitomo K, Maruyama J, Kikuchi K, Hasebe N; CAMUI investigators. Combination of antihypertensive therapy in the elderly, multicenter investigation (CAMUI) trial: results after 1 year. J Hypertens. 2013 Jun;31(6):1245-55. 42. Nishimura H, Shintani M, Maeda K, Otoshi K, Fukuda M, Okuda J, Nishi S, Ohashi S, Kato S, Baba Y; on behalf of the Biriken Study Group. Which is a Better Treatment for Hypertensive Patients with Diabetes: A Combination of Losartan and Hydrochlorothiazide or a Maximum Dose of Losartan? Clin Exp Hypertens. 2013 Mar 15.    [ Содержание выпуска N 3 | Выпуски журнала | Список журналов ]